TrialHuman vaccines & immunotherapeutics2022

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.

Suvimol Niyomnaitham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.